loadpatents
Patent applications and USPTO patent grants for Adang; Anton Egbert Peter.The latest application filed is for "antagonistic anti-human cd40 monoclonal antibodies".
Patent | Date |
---|---|
Antagonistic anti-human CD40 monoclonal antibodies Grant 11,396,552 - Adang , et al. July 26, 2 | 2022-07-26 |
Antagonistic Anti-human Cd40 Monoclonal Antibodies App 20210101991 - Adang; Anton Egbert Peter ;   et al. | 2021-04-08 |
Improved Anti-fibronectin Eda Antibodies App 20210095011 - ADANG; Anton Egbert Peter ;   et al. | 2021-04-01 |
CD40 Signalling Inhibitor and a Further Compound, Wherein the Further Compound is a Bile Acid, a Bile Acid Derivative, an TGR5-Receptor Agonist, an FXR Agonist or a Combination Thereof, for the Treatment of Chronic Inflammation, and the Prevention of Gastrointestinal Cancer or Fibrosis App 20160151486 - Adang; Anton Egbert Peter ;   et al. | 2016-06-02 |
S-mirtazapine For The Treatment Of Hot Flush App 20130225559 - Peeters; Bernardus Wijnand Mathys Marie ;   et al. | 2013-08-29 |
S-mirtazapine For The Treatment Of Hot Flush App 20120302552 - Peeters; Bernardus Wijnand Mathys Marie ;   et al. | 2012-11-29 |
S-mirtazapine For The Treatment Of Hot Flush App 20100267694 - Peeters; Bernardus Wijnand Mathys Marie ;   et al. | 2010-10-21 |
S-Mirtazapine For The Treatment Of Hot Flush App 20070265245 - Peeters; Bernardus Wijnand Mathys Marie ;   et al. | 2007-11-15 |
Bisaryl derivatives having FSH modulatory activity Grant 6,900,213 - Guo , et al. May 31, 2 | 2005-05-31 |
Bicyclic heteroaromatic compounds useful as LH agonists Grant 6,841,553 - Gerritsma , et al. January 11, 2 | 2005-01-11 |
Bisaryl derivatives having FSH modulatory activity App 20040152703 - Guo, Tao ;   et al. | 2004-08-05 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.